|
Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
CMC Markets accredited as NZX Participant
June 18th Morning Report
PCT - Sale of PwC Tower to New Investment Partnership
MEL - Waitaki reconsenting receives final approval
June 15th Morning Report
Devon Funds Morning Note - 12 June 2026
June 11th Morning Report
SKO - Leadership Update
June 8th Morning Report
RBNZ announces decision on use of the word "bank"